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A Chemical Perspective on the
Anthracycline Antitumor Antibiotics
by Beth R. J. Abdella* and Jed Fisher*t
The anthracycline antitumor antibiotics occupy a central position in the chemotherapeutic control of
cancer. They remain, however, antibiotics ofthe last resort and thus exhibit toxicity both to the neoplasm
andtothe host organism. As part ofthe continuing effort to dissociate the molecularprocessesresponsible
for these two separate toxicities, attention has been drawn to the intrinsic redox capacity of their tetra-
hydronapthacenedione aglycone moiety, and to the possible expression ofthis redox activity againstthose
biomolecules for which anthracyclines have a particular affinity (polynucleotides and membranes). This
review is a synopsis of the present trends and thoughts concerning this relationship, written from the
point ofview ofthe intrinsic chemical competence ofthe anthracyclines and their metabolites. While our
ignorance is profound-the precise molecular locus of the antitumor expression of the anthracyclines
remains unknown-there is now evidence that the relationship ofthe anthracyclines tothe DNA (possibly
requiring enzymatic cooperation) and to the membranes, with neither event requiring redox chemistry,
may comprise the core of the antitumor effects. The adventitious expression of the redox activity under
either aerobic conditions (in which circumstances molecular oxygen is reduced) or anaerobic conditions
(in which circumstances potentially reactive aglycone tautomers are obtained) is therefore thought to
contribute more strongly to the host toxicity. Yet little remains proven, and the understanding of the
intrinsic chemical competence can do little more than lightly define the boundaries within which are
found these and numerous other working hypotheses.
Introduction
Overthe past decade the anthracycline antitumor an-
tibiotics (Fig. 1), exemplified by Adriamycin (doxorub-
icin) and daunomycin (daunorubicin), have attained a
central position in the chemotherapeutic control of can-
cer (1-8). As a consequence of their relative breadth
and potency, considerable effort has been expended to
discern the molecular mechanisms of their activity.
Progress has, however, been painstaking, and only re-
cently has order begun to emerge from chaos. This re-
view is a distillation of the current thoughts and ideas
emerging from these experimental endeavors, with a
particular emphasis upon the role of redox transfor-
mations. The focus is placed upon the relevant chemical
and biochemical events, and as such, medical progress
with the anthracyclines is not covered. Literature ci-
tations are selective, and are drawn from the primary
literature ofthe past three years, through the summer
of 1984.
A systematic organization to this paper is made most
difficult by the extraordinary complexity exhibited by
the anthracyclines in the living organism. There is now
a consensus thatmultiple pathwaysexistforthe expres-
sion of anthracycline cytotoxicity, and that the full
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expression of any one anthracycline is a linear combi-
nation ofall pathways. Unraveling these pathways into
those that are desirable (toxicity to the neoplasia) and
into those that are not (toxicity to the organism) is an
enigma, only recently rendered less inscrutable. Ac-
cordingly, a chemical organization is chosen, where
progress in the chemistry ofeach pathway is evaluated
and an effort then made to place the chemistry into the
appropriate biological context.
We begin with an evaluation ofthe basic redox chem-
istry ofthe anthracyclines, and explore the enzymology
appropriatetomediatingthesereactions. Therelevance
ofthe cellular DNA as a target ofthe anthracyclines-
with or without redox activation-and the potential
consequences of metal ion chelation are then covered.
At this point the enormous separation that yet exists
between the chemical and biochemical knowledge will
be apparent. A summation of the capacity of the cell
membrane as a target is provided and is followed by a
synopsis of the role of redox processes to the antineo-
plastic activity. From these perspectives, the working
hypothesis is suggested that the redox capacity of the
anthracyclines may represent an undesirable pathway,
while nucleic acids and membranes may represent the
focus for the desirable expression of anthracycline ac-
tivity. Yet the precise chemistry remains elusive and
shallremain so untilthe precise locusforthe expression
of anthracycline antitumor activity has been identified
to the satisfaction ofall interested parties. Bythis fact,
all commentary within this review is qualified.ABDELLA AND FISHER
Redox Chemistry of the
Anthracyclines
Anaerobic Chemistry: The Chemistry of
the Quinone Methide
Metabolic transformation ofa drug as a prerequisite
to the expression ofits biological activity is now under-
stood to be a common occurrence. Moore (9,10) was the
firsttonotethattheanthracycines (amongothers) com-
prise a family where bioreduction could lead to reactive
intermediates capable of nucleophile alkylation ("bio-
reductive alkylation") (11). A most reasonable inquiry,
then, concerning the anthracycines is the relationship
of this chemistry to their biological activity. Do they
alkylatebiomolecules, and, ifso, doesthisprocessdefine
the antitumor activity, the general toxicity, neither, or
both? Only most recently has our understanding ofthe
anthracycline chemistry progressed to a point where
the experimental design meaningfully addresses the ki-
neticandchemicalcompetenceofMoore'sintermediates
(quinone methides). While a definitive answer has not
been possible, the general outlines ofthe quinone meth-
idechemistryarenowdefined, andadescriptionofthese
outlines comprises this section.
I< 2C
H3 0 H R
To begin with, quinone methide formation is an an-
aerobic eventthat may occur once and only once forany
one individual anthracycline molecule. Anthracyclines,
as quinones, are intrinsically capable of redox chemis-
try. At carbon 7is found an oxygen substituent, usually
aglycoside, that is transformed from astable functional
group in the quinone to a stable leaving group in the
hydroquinone. As the hydroquinone itselfis quite prone
to oxidationby 02, onlywhen 02is absentwill itpersist
long enough (and this need not be long at all) for this
leaving group ability to be expressed. Intramolecular
loss ofthis C-7 substituent provides the quinone meth-
ide intermediate [Eq. (1)]. The quinone methide may
be envisioned to behave as a nucleophile, to react with
an electrophile to yield a C-7 functionalized quinone; or
tobehave as anelectrophile to yield aC-7functionalized
hydroquinone. This latter hydroquinone may re-elimi-
nate to the quinone methide unless a suitable oxidant
is present to convert this adduct to the stable quinone
state (12,13). If no suitable reagent to react with the
quinone methide is present, it will react with a proton
(an electrophile) to provide a 7-deoxy aglycone or react
with itself to provide a 7,7'-dimer. In both instances
the quinone methide character is irrevocably lost.
The balance between these various reactions is de-
termined by the overall substitution of the particular
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FIGURE 1. Anthracyclines and anthracyclinones. (1) Daunomycin family: (la) daunomycin (R = L- daunosamine, R' = H); (lb) 7-deoxydau-
nomycinone (R = R' = H); (1c) daunomycinone (R = OH, R' = H); (id) Adriamycin (R = L-daunosamine, R' = OH); (le) epirubicin (R
= 4'-epi-L-daunosamine, R' = OH). (2) Aclacinomycin family: (2a) aclacinomycin A (R' = L- rhodosamine-2-deoxy-L-fucose-L-cinerulose
A, R = H); (2b) 7-deoxyaklavinone (R = R' = H). (3) Bi(7- deoxyaklavinon-7-yl). (4) Nogalamycin family: (41) nogalamycin (R = H, R'
= nogalose, R" = CO2CH3); (4b) 7-deoxynogalarol (R = R' = H, R" = C02CH3); (4c) 7R-nogamycin (R = nogalose, R' = R" = H); (4d)
menogarol (R = OCH3, R' = R" = H); (4e) epimenogarol (R' = OCH3, R = R" = H); (4f) 7-deoxynogarol (R = R' = R" = H).
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anthracycline. At present, three different subgroups
are recognized; it is likely, however, that others exist
as not all anthracyclines have been carefully examined.
These three groupings do contain those anthracyclines
ofprimary clinical interest. The first consists of 11-hy-
droxy anthracycines (including daunorubicin, Adria-
mycin, and epirubicin; and presumably including Ad-32
and esorubicin); the second the 11-unsubstituted an-
thracyclines (including aclacinomycin, 11-deoxydauno-
mycin, and marcellomycin); and the third the nogala-
mycin family (including nogalamycin itself and
menogarol). Comparison ofthe three families indicates
that the two features of the quinone methide most
strongly affected are the rate constant for quinone
methide formation and the balance between the elec-
trophilic and nucleophilic character of the quinone
methide.
Access to the quinone methide from daunomycin may
be hadfrom anaerobic reduction ofthe quinone ineither
organic or aqueous solvent. The reducing agent used by
Koch and colleagues (14-17) in their extensive study of
the quinone methide in organic solvent is the mero-
stabilized 3,5,5-trimethyl-2-oxomorpholin-3-yl radical.
This is a uniquely suitable reducing agent for quinone
methide production in that it is stable in the absence of
an oxidant, a strong and rapid reducing agent in the
presence of an oxidant, and possesses complete regi-
ochemistry for quinone reduction over C-13 carbonyl
reduction. Daunomycin reduction in aqueous solution is
most conveniently done with NAD(P)H as the penul-
timate reducing agent and an enzyme catalyst,
NADP:ferredoxin oxidoreductase from spinach (18), as
the ultimate reducing agent. In both cases, spectro-
scopic examination reveals the essentially immediate
formation ofthe quinone methide from the daunomycin
hydroquinone, observing at the X__. of the quinone
methide near 600 nm. Without an appropriate electro-
phile or nucleophile present, it decays by solvent pro-
tonation at C-7. This reaction has apparent first order
kinetics, andindicatesalifetimeforthequinonemethide
of approximately one minute (t½ for the decay for the
quninone methide is 15 sec at pH 8.0, 30°C).
The daunomycin-derived quinone methide displays
nucleophilic character toward electrophiles of compa-
rable reactivity to H+ . The one functional group found
to qualify thus far is the aldehyde (15,16,18). Quinone
methide trapping at the re face is followed by intra-
molecular hemiacetal formation at the C-13 carbonyl.
Weaker electrophiles, such as oxidized glutathione, do
not react to yield stable adducts. Whether the bimolec-
ular rate constant is too low, or whether it is that hem-
iacetal formation is a required event to stabilize the
adduct (vide infra), is undecided. Since, however, suit-
able electrophiles in vivo are uncommon, and the bi-
molecular rate constant even for aldehydes low (-1
MW'-sec'1), it may safely be speculated that only rather
common and innocuous electrophiles-such as glycer-
aldehyde-3-phosphate, as arepresentativeglycolytic in-
ternediate-may react. The one qualification to this
speculation is the possibility that quinone methide for-
mation occurs after complexation of the anthracycline
to a critical cellular target, where an otherwise weakly
reactive functional group is compelled to participate by
its proximity.
The daunomycin-derived quinone methide may also
undergo trapping by nucleophiles. The forination of a
stable adduct from nucleophilic trapping ofthe quinone
methide requires a subsequent oxidation step; the sub-
tleties of these reactions are discussed elsewhere (12).
Only one nucleophile, N-acrtylcysteine, has been found
thusfartohave significantbimolecularreactivity tothis
quinone methide (K. Ramakrishnan and J. Fisher, un-
published data). A comprehensive examination of the
nucleophile reactivity has yet to be made, and in any
case the identical caution with respect to specific trap-
pingas is made intheprecedingparagraphapplies here
as well.
Aclacinomycin A is the representative anthracycline
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from the second anthracycline family with respect to
quinone methide reactivity, the 11-deoxy anthracy-
clines. This anthracycline contains several other fea-
tures that differentiate it from the daunomycin family,
including a C-7 trisaccharide, an unoxidized carbon at
C-14, and the 1OR-carbomethoxy moiety. Initial anti-
tumor evaluation suggests it to be a somewhat less po-
tent, but also less toxic, anthracycline. Its clinical ef-
ficacy is now being established.
Like daunomycin, the aclacinomycin hydroquinone
rapidly eliminates to the quinone methide. This quinone
methide is not as stable as that from daunomycin, pri-
marily as aconsequence ofasecond reaction pathway-
in addition to solvent protonation-available to it. Ex-
amination of the reaction products obtained in the ab-
sence of other nucleophiles or electrophiles shows that
two compounds are formed: 7-deoxyaklavinone, from
solvent protonation; and bi-(7-deoxyaklavinon-7-yl), a
7,7'-dimer from quinone methide coupling (17).
Efforts to trap this quinone methide with the alde-
hydes capable of adduct formation with the 7-deoxy-
daunomycinone quinone methide tautomer, have not
been successful. This does not, however, necessarily
abrogate the quinone methide ofnucleophilic character;
it does, after all, react with the proton. A possible ex-
planation is that aldehyde adducts do form, but the ab-
sence of the C-14 ketone precludes the stabilizing for-
mation of the hemiacetal, and the adducts revert.
Indeed, preliminary experiments indicate that an al-
dehyde adduct can be obtained from 11-deoxydauno-
mycin (which has the C-14 ketone). This anthracycline
may best represent the structural and mechanistic
bridge between daunomycin and aclacinomycin.
The aclacinomycin-derived quinone methide is more
easily trapped by nucleophiles in the presence of oxi-
dants than is that fromdaunomycin. These nucleophiles
are, however, limited tothiols, and do not include more
relevant nucleophiles such as enols or phosphate esters
(such as GMP). Although negative results with GMP
may reflect on the possibility of covalent DNA modifi-
cation, it must be remembered that mononucleotides
significantly underestimate the reactivity of oligonu-
cleotides as nucleophiles (19,20).
Nogalamycinistheparentstructureforthethirdfam-
ilyofanthracycline-derived quinonemethides. Itdiffers
fundamentally from the preceding two by having its
aminoglycoside fused to the D, rather than the A, ring;
by a neutral sugar at C-7; and by the uncommon 7S,
9S, 1OR (epimeric at C-9) configuration (21,22). Inter-
estingly, the nogalamycin derivative with the most
promising clinical antitumor efficacy, menogarol, is a
semisynthetic derivative wherethe C-7glycosideis lost
and replaced with an epimeric methoxy. This change is
observed to significantly weaken the in vitro DNA af-
finity (23,24). The chemistries ofnogalamycin and men-
ogarol upon anaerobic reduction display very different
characteristics compared to the other two classes.
Ratherthan immediately yielding the quinone methide,
as is the case for daunomycin and aclacinomycin, their
respective hydroquinones slowly decay to the quinone
methide, ultimately givingthe 7-deoxy aglycone. Thus,
quinone methide formation, and not its protonation, is
rate-limiting for these products. Trapping experiments
have not been attempted, asit is likely thatthe quinone
methide has an insufficient steady state concentration
to afford appreciable bimolecular reactivity.
A reasonable hypothesis for this dramatic change in
the rate of quinone methide formation is that this in-
tramolecular elimination is under stereoelectronic con-
trol, and that a periplanar orientation between the in-
tramolecular nucleophile, the w bond, and the leaving
group, the C-7 substituent, is required to minimize the
activationenergy. Thus, whileforbothdaunomycin and
aclacinomycin the leaving group has available the more
labile pseudoaxial position, this may not be the case for
nogalamycin. Howevermenogarol, beingepimeric at C-
7, has the pseudoaxial position available (25). Yet it
reacts only somewhat faster than nogalamycin (18).
Since within this familyleavinggroup stability does not
influence the reaction rate, it must be concluded that
stereoelectronics alone is insufficient to account for the
slow rate of quinone methide formation within the no-
galamycin family. Interestingly-and in something of
acontrasttothis conclusion-Arcamone and colleagues
(26)havebeenabletoapplywithexcellentsuccessthese
same stereoelectronic principles to account for the rel-
ative ability to yield the quinone methide within the
daunomycin and 6-deoxydaunomycin families. Clearly
the full complexity of this problem has yet to be
appreciated.
This same conclusion pertains to the chemistry ofthe
quinone methide itself. Only first indications of its be-
havior are available for three anthracycline classes; at
least two anthracycline families of clinical interest are
as yet unevaluated (4-demethoxydaunorubicin and 6-
deoxydaunorubicin). Nonethelessallpresentlyavailable
evidence indicates that the bimolecular reactivity of
these quinone methides is surprisingly low. Krohn and
colleagues have, however, provided excellent circum-
stantial evidence that under chemically more vigorous
conditions a greater expression of reactivity may be
manifested (27). If, then, quinone methide formation is
a particular event for the expression of the anthracy-
cline antitumor activity, a common behavior must be
enforced by the target to which the anthracycline is
complexed. Since quinone methide formation occurs
only once, the anthracycline must form, this complex
prior to reduction. It is concluded that without a mo-
lecular knowledge ofthat target, the importance ofthe
anaerobic reductive activation of the anthracyclines is
not ascertainable.
Chemistry of the Anthracycline
Semiquinone
As quinones, anthracyclines are capable ofaccepting
electrons in one electron increments, thus forming se-
miquinone radicals. The relationship of these radicals
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tootherbiologicalphenomenaremains amajorresearch
focus. The basic aspects of the daunomycin semiqui-
none's chemistry are now established. One-electron re-
ductionofthequinonebyelectrochemical (28,29), chem-
ical(16) orenzymatic (30)means leadsto an EPR signal
characteristic of the daunomycin semiquinone (31,32).
The disproportionation equilibrium lies welltoward the
hydroquinone and quinone, as spectrally detectable
quantities ofthis radical are not observed during titra-
tions. This is equally true for the aclacinomycin semi-
quinone (17). Lown and co-workers (28), by electro-
chemical measurement, provided the first value for the
twoelectronreductionmidpointpotentialof-0.64V (vs.
SCE) for daunomycin; further studywith additional an-
thracyclines indicates that there are substantial sub-
stituent effects on this potential (ranging from -0.70 V
for carminomycin to -0.50 V for aclacinomycin) (33). As
would be expected, the daunomycin semiquinone is a
labile and powerful reductant toward one-electron ac-
ceptors, includingmetals (34) and organic oxidants (35),
and last but not least oxygen (36). Electron transfer to
oxygenissufficiently fasttoprevent thereductive elim-
ination ofthe C-7substitutent underaerobicconditions.
A detailed pulse radiolysis study has established the
one electron reduction potential for Adriamycin as
-0.328 V (vs. NHE, pH 7), which may be combined with
the one electron potential for 02 of-0.155 V to provide
an equilibrium constant of 0.0012 for electron transfer
from 02 toAdriamycin, togive 02andthe semiquinone
(36). In all the above respects the semiquinone chem-
istry is rather ordinary.
There are, however, two aspects to the semiquinone
chemistry that remain uncertain. In order to place its
involvement in lipid peroxidation in a reasonable chem-
ical setting, it has been presumed that the semiquinone
is competent for the reduction ofalkyl peroxides to the
hydroxyl radical (37,38). Indeed, spin-trapping exper-
iments are consistent with this notion (38,39). Direct
evidence for this reaction has been provided by Kaly-
anaraman et al. (40), where the effect of H202 on the
steady state semiquinone concentration during enzy-
matic reduction hasbeenused to estimate abimolecular
rateconstant ofabout 103-104M-1sec-1 forthisreaction.
Onthe otherhand Houee-Levin et al. (41), usingexcess
C02- asreductant, find noevidence forthisreactionbut
ratherfor 2e- reduction, from the hydroquinone, to the
peroxide to yield water. A most reasonable explanation
is that both reactions are possible, with the balance
between the two determined by the availability ofelec-
trons to the anthracycline. However, with respect to
the semiquinonereductionofperoxidesthecontribution
frommetal catalysis remains problematical (40,42). The
second uncertainty is the contribution of the semiqui-
none to the reductive deglycosylation reaction. A prev-
alent assumption in the literature is that this reaction
is reserved to the semiquinone, and not to the hydro-
quinone. In support ofthis notion are the observations
that the one electron-transferring flavoenzymes are
quite generally more active as catalysts ofthis reaction
thanthetwo-electrontransferringdehydrogenases(43),
and the good correlation between the semiquinone
steady state concentration and extent of 7-deoxy agly-
cone formed (30). However, the first observation may
reflect more that these enzymes are generally stronger
reducingagents, and have alowersubstrate specificity.
Since they are capable ofoverall two electron transfer,
they may produce the hydroquinone as well as the se-
miquinone. The second observation applies equally well
to the hydroquinone as to the semiquinone, since in the
course ofanthracycline reduction the semiquinone may
be seen in direct proportion to the overall forward ve-
locity to the hydroquinone. Thus, these data alone will
not distinguish the semiquinone from the hydroquinone
as a competent intermediate forthis reaction. Further,
the failure of previous efforts to detect hydroquinone
intermediates is explained both by a lack ofknowledge
as to their properties-it was not certain what to look
for-and as a result ofthe aqueous insolubility ofmany
of the 7-deoxy aglycones. Aglycone precipitation may
be quite competitive withreduction. Nonethelessunder
the appropriate experimental circumstances the com-
petence of the anthracyclines for overall two electron
reduction is easily established (44,45); moreover their
competence in the elimination reaction to the 7-deoxy
aglycone quinone methide tautomer is firmly estab-
lished (12,16,17). Thus while the semiquinone has not
been excluded from this reaction, neither is there any
evidence that demands it be included. A final point to
be made concerns the product ofthe (as yet unproven)
elimination reaction from the semiquinone glycoside,
the C-7 benzyl radical. This neutral radical has been
frequently spoken of as a potentially reactive inter-
mediate, in accounting for the presumed covalent la-
beling ofmacromolecules upon anaerobic anthracycline
reductive activation. The reactivity of this radical is
questionable. Radicals behave as reducing agents, as
electrophiles toward each other, and less frequently as
radical abstractors. Given the resonance stabilization
available to the C-7 benzylic radical and the behavior
of the hydroquinone-derived quinone methide, it ap-
pears most unlikely that it would be chemically com-
petent for bimolecular attack as an electrophile on cel-
lular macromolecules.
A Redox-Incapacitated Anthracycline
A singular anthracycline analog is 5-iminodaunorub-
icin, developed by Acton and colleagues (45). This an-
alog provides an excellent contrast to daunorubicin, as
replacement ofthe oxygen with nitrogen virtually abol-
ishes its redox capability, but not antitumor activity.
Byvirtue ofits quinoneimine C-ring, it atoncebecomes
ananalogbothmoredifficulttoreduceandmoredifficult
to reoxidize (47). Hence 7-deoxy metabolites are not
observed in vivo, and its toxicity toward cardiac tissue
is substantially diminished (48,49). Nor is it a pro-drug
for daunorubicin; the imine moiety is quite hydrolyti-
cally stable. Its poor redox ability is somewhat sur-
prising and must clearly be related to the overall elec-
tron-donating substitution elsewhere in the
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anthracycline (at C-4, 6 and 11); quinone imines having
even modest electron-withdrawing substitution are
very potent electrophiles (50,51). The absence ofredox
capability has the following consequences. Futile oxy-
gencyclingisvirtuallyabsentcomparedtodaunorubicin
(48), and lipid peroxidation is therefore abolished (52-
54). The quinone imine also influences otherproperties.
5-IminodaunorubicinisapoorinhibitorofnuclearrRNA
synthesis, and although it possesses typical behavior
toward DNA as an intercalator, it has a somewhat
smalleraffinity (55). As discussed more fullybelow, this
intercalation also affects the topoisomerase II enzyme
but in a fashion still dissimilar to daunorubicin (56).
Last, it provides excellent evidence for redox activity
contributing more toward undesirable toxicity than tu-
mor toxicity; it retains antineoplastic activity at poten-
ciesquitecomparabletodaunorubicin invitroandsome-
what less in vivo (56). It is not, however, a nontoxic
anthracycline, as elevated dosing does result in toxicity
believed to be associated with a membrane effect, and
not originating fromredox activity (49). Thus while this
anthracycline in not necessarily an improved antitumor
antibiotic-although it is certainly being evaluated for
this possibility-it (as well as other new derivatives)
offers optimism that substantial improvements in the
therapeutic ratio may be attained by subtle structural
alterations.
Metal Ion Modulation of Redox Activity
An aspect that has only recently received its proper
scrutiny is the effect of metals, particularly Fe(II),
Fe(III), and Cu(II), on the anthracycline redox chem-
istry. The ability ofmetals to strongly potentiate aero-
bic peroxidation has been recognized for some time
(57,58) as has the chelating ability of il-hydroxy an-
thracyclines, such as daunomycin and Adriamycin (6).
The consequences ofmetal chelation to daunomycin ap-
pear to be dramatic, resulting in an overall increase in
electrophilicity, as would be expected. Metal chelation
occurs to the 11,12 oxygens (6), providing a complex
that is reduced by simple sulffiydryls (glutathione, cys-
teine) whereas the uncomplexed anthracycline is not.
Under aerobic conditions, the electrons derived from
the sulfhydryl are passed to 02, providing H202 that is
used in the complex-dependent degradation of lipids,
deoxyribose, and DNA (59-63). With respect to this
latterreaction, Myersetal. (64) haveprovided evidence
that not only is the complex significantly more active
than either component alone, but that complex associ-
ation to DNA is specific, remarkably stable, and fun-
damentally different than the intercalation that occurs
with the free anthracycline. The chemistry associated
withthe DNAcleavage suggests that the anthracycline
serves primarily to stabilize the DNA complex, rather
thanto assume adirectredoxrole (this isthenreserved
to the iron). Although there exists no direct evidence
thattheiron-anthracyclinecomplexformsinvivo, there
are substantial circumstantial data consistent with this
notion, summarized by Eliot et al. (63), which further
indicate that the complex may represent a component
of the cardiac toxicity.
Even fewer data are available concerning the chem-
istry ofthis complex under hypoxic conditions. Zweier
(65) has described direct evidence forthe complex's role
in 02reduction, and observes thatunderanaerobic con-
ditions the Fe(III)-Adriamycin complex slowly con-
verts to the Fe(II) complex, presumably using the an-
thracycine as the reducing agent. Admission of 02
immediately restores the Fe(III) oxidation state. Com-
plementary observations are also reported by Gutter-
idge(66). Myersetal. (62)havetreatedtheironcomplex
anaerobically with glutathione; 7-deoxyadriamycinone
is not formed. This suggests that quinone methide for-
mation does not occurfromthe complex. However, this
pointhasnotbeenpressed, andfurtherexperimentation
(particularly with stronger reducing agents) is neces-
sary to settle this possibility. Should the quinone meth-
ide-iron complex form, the metal will accentuate the
electrophilic character ofthe quinone methide and con-
ceivably allow a broader range ofreactivity than is ob-
served forthe uncomplexed quinone methide. This may
also conceivably confer redox activity to an anthracy-
cline otherwise thought inert, in particular 5-iminodau-
norubicin (vide supra). Finally, metal chelationdoesnot
occur for 11-deoxyanthracyclines (64,67) possibly ex-
plaining their generally lower cardiac toxicity.
Chemistry of the 7-Deoxyaglycones
A potentially interesting and important aspect ofan-
thracycline redox chemistry that has received little at-
tention is the chemistry ofthe 7- deoxyaglycones. The
extensive studies on anthracycline metabolism by
Schwartz and colleagues (68,69) have unearthed an
abundance of structurally unidentified metabolites.
Within the chemistry of the aglycones may be found
suggestions for structures for these metabolites. Apart
fromthis possibility, therationale forthe studyofthese
aglycones is straightforward and easily defended. Qui-
none methide formation occurs subsequent to the first
anaerobic reduction ofthe anthracycline. One maymost
reasonably presume then that the major product from
the quinone methide-the C-7 deoxyaglycone, by sol-
vent protonation-will also serve as a substrate forthe
enzyme catalyst that first gave rise to the quinone
methide.
Indeed, initial examination reveals that 7-deoxydau-
nomycinone is reduced chemically and enzymatically
with the same alacrity as the parent glycoside. This
would be ratherprosaic chemistry, ifallthatitinvolved
was overall two electron reduction to the 7- deoxydau-
nomycinone hydroquinone. Recent studies indicate this
hydroquinonetobearatherinterestingchemicalentity.
Whileretainingtheanticipated labilitytoward oxidants
(44,45), ifanaerobic conditions persist (to allowit area-
sonable lifetime) it may behave as a strong hydride do-
nor, as noted by Koch and colleagues (70); or to oth-
erwise undergo spontaneous tautomerization to the
more stable leuco tautomers [Eq. (2)]. These tautomers
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(5) are brightyellow and strongly blue fluorescent com-
pounds, that in the absence ofbase remain quite stable
to oxygen oxidation (D. Brand, unpublished data). Al-
though the spontaneous tautomerization is slow, this
reaction may be catalyzed by metal ions and it would
not be at all unreasonable to anticipate the formation
of these tautomers in vivo. Further, these leuco tau-
tomers retain a capability as redox agents in that they
areobserved toundergo slowoxidation byH202toyield
aproduct tentatively identified as the quinone (6). This
latter reaction is accelerated by horse radish peroxi-
dase. Should this quinone indeed be the product, it may
behave as a potent oxidant and possibly as an electro-
phile as well. While much ofthis chemistry is new and
certainly speculative, it may offer further insight into
anthracycline behavior in vivo, and may allow a better
understandingofthemetabolismofthese quinones. The
nature and characteristics ofthese reactions invivo are
likely to be quite different from that ofthe glycosides,
as a consequence of the much greater lipophilicity of
the aglycones.
Enzymology of Anthracycline Redox
Activation
Thereareanumberofdifferentredoxprocessesavail-
able to the anthracyclines. In order to determine the
pathways followed in vivo, the identification of the bi-
ological molecules which interact with these antibiotics
must be made. Since the anthracyclines are absolutely
dependent on enzymatic catalysis for their reduction, a
particular focus is placed upon those enzymes involved
intheseevents. Unfortunately, itappearscharacteristic
of reductive metabolism that the enzymes that partic-
ipate are used adventitiously (71); that is to say there
are no specific "anthracycline reductases" but rather
enzymes whose catalytic capacity is usurped, and di-
verted to electron transfer to the oxidant. In these cir-
cumstances it is not possible to identify the enzyme(s),
but rather only to make an educated determination on
the basis of relative organelle ability, and relative en-
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zyme availability within the organelle. Progress with
respectto the anthracyclines continues, and asummary
ofthe current knowledge ofthe enzymology associated
with the biological activities ofthe anthracycines may
be provided.
Many of these studies have centered on the heart.
This is the obvious consequence of the fact that the
cardiotoxicity associated with anthracycline adminis-
tration is therapy limiting, and the probable association
ofredox activity to this cardiotoxicity. Doroshow (72),
beginning with the observation that 02 consumption
(and 02- production) by heart cell homogenates is sig-
nificantly enhanced by the presence ofAdriamycin, has
examinedthedifferentcharacteristicsandcontributions
of the cytosol, sarcosomes, and mitochondria. All cat-
alyzeaerobic anthracycline-mediated oxygenreduction.
Superoxide production by the sarcosomes requires
NADPH, is inhibited by NADP+, and accumulates
H202. This suggests that the reducing equivalents are
provided by NADPH:cytochrome P-450 reductase. In
the cytosol, oxygen depletion involves NADH and is
significantly inhibited by allopurinol, thus implicating
xanthine oxidase as the catalyst. NADH is also the re-
ducing agent in the mitochondrion, and anthracycline-
mediated 02 reduction is inhibited by excess NAD+ or
rotenone. These facts implicate the NADH dehydro-
genase (although other enzymes cannot be entirely ex-
cluded), and indeed Doroshow has provided direct evi-
dence with a purified NADH dehydrogenase
preparation (73).
Since many of the active antitumor anthracyclines
accumulate in the nucleus, and since the nucleus con-
tains the obvious target (but yet unproven target) of
the anthracyclines, the DNA; a considerable effort has
been put to determining the redox capability ofthe nu-
cleus. This effort has been rewarded with the isolation
of nuclear enzymes by Bachur and colleagues (74) ca-
pable ofanthracycline reduction. Indeed, it is probable
thatthenucleusisgenerallycapable ofdrugmetabolism
(75). The particular identity of the nuclear reductase
enzyme is as yet unestablished; it may correspond to
either or both cytochrome P-450 reductase or xanthine
5
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oxidase as the nucleus has both ofthese enzymes. Re-
ductive activation of the anthracyclines in the nucleus
is therefore a probable event.
A requirement for nuclear anthracycline-metaboliz-
ing enzymes is presumed by the anticipated brief life-
time ofthe activated intermediates (76). For good rea-
son, one envisions anthracyline activation at the target
site, to avoid the necessity of the intermediate trav-
ersing large distances. However, one does not need to
have the anthracyclines within the nucleus in order for
the nuclear DNA to be damaged. In particular, Nudd
and Wilkie (77) argue that since the mitochondrion is
knowntobe quite susceptible todrug-mediated damage
(perhapsmoresothanthenucleus), andsinceitcontains
DNA also quite susceptible to covalent modification
(78), that the DNA of the mitochondrion might repre-
sent a specific target ofanthracyclines. Completing the
circumstantial evidence infavorofthishypothesis isthe
observation that mitochondrial DNA migrates to the
nucleus (79). Nor is NADH dehydrogenase the only
candidate inthe mitochondrion forthis reaction. Atten-
tion is drawn to this enzyme both by its classification
as a low potential flavoenzyme (43) and by Doroshow's
studies (72,73); however, the observation that low po-
tential iron-sulfur centers are chemically competent an-
thracycline reductants (18) opens the range ofpossibil-
ities to other enzymes. While it is possible that these
may be minor contributors to the overall reduced ox-
ygenflux, the inhibition ofthese enzymes ifspecific and
potent, may contribute to cytotoxicity. It is noted in
passingthatnitroimidazole activationasanantiparasitic
antibiotic occurs at low potential iron-sulfur centers
(80,81). In many respects, the overall features of this
hypothesis are reminiscent ofFolker's hypotheses con-
cerning the relationship of mitochondrial injury to the
acutetoxicity ofanthracyclines (82). Thus, the stage for
anthracycline reductive activation inthese organelles is
set, with the nucleic acids and membranes plausible
recipients ofthe consequences.
Oligonucleotides as Anthracycline
Targets
The relationship between the anthracyclines and nu-
cleicacids isonethathasbecomelessdistinctwithtime,
as the measure ofits complexity has evolved (5). As it
now stands, this relationship consists of two known
parts; the first involving the consequences ofnonredox
associated processes (primarily derived subsequent to
intercalation) and the second involving the conse-
quences of redox processes, also following DNA asso-
ciation (but not necessarily requiring intercalation).
Intercalation and Related Phenomena
An ability of anthracyclines to intercalate DNA was
one ofthe firstbiologicalproperties established; and for
some period oftime thereafter the correlation between
antitumor potency and intercalation was presumed to
be a requisite for antitumor ability (1). With the bio-
logicalevaluationofnewanthracyclines, found toretain
antitumoractivityyetwithdiminishedaffinityforDNA,
the situation is now much less certain (83), although it
cannot be disputed that within the Adriamycin family
an excellent correlation exists between antibiotic effi-
cacy and DNA affinity. There are however anthracy-
clines that are active; and inhibit DNA and RNA syn-
thesis near equally (Adriamycin), or RNA
preferentially (aclacinomycin), or poorly inhibit either
(menogarol).
As befits their present importance in chemotherapy,
Adriamycin and daunomycin have been most exten-
sively examined with respect to DNA binding. There
is general agreement that they behave as "classic" in-
tercalators, binding through the minor groove with the
BCringslyingskewtothebasepairs, andtheC-7amino
sugarrestingwell within the minor groove (84-87). De-
pending on conditions, the binding may occur cooper-
atively ornot (88); and there is adistinct preference for
B rather than Z DNA (89). Although early studies sug-
gestedaGCbasepairpreference, therearerecentstud-
ies indicating little apparent sequence specificity
(90,91). In this regard however, a caution must be
placed upon the inference of the true biological locus
from mere binding data (92). There is little doubt that
daunomycin binding to nucleosomes is rather different
than to free DNA; Chaires et al. (93) suggest a pref-
erence of daunomycin for genetically active DNA re-
gions having less nucleosomal structure. In any case,
DNA affinity may be virtually abolished byN-acylation
of daunosamine with retention of antitumor activity
(94,95). (Whether or not these are mere pro-drugs, lib-
erating the free aminoglycoside by acylase-catalyzed
hydrolysis, remains uncertain). These observations
again underscore the difficulty in separatingthe impor-
tant from the extraneous observations while the source
for the molecular expression of anthracycline activity
remains unknown. Given only our present knowledge
ofthe plasticity ofthe DNA helix (96-99), we may rea-
sonably inquire if any in vitro system is truly appro-
priate to these questions.
The 11-unsubstituted anthracyclines (such as aclaci-
nomycin and marcellomycin) by all indications bind to
DNA in a fashion quite similar to daunomycin
(83,85,100). The spectral and fluorometric changes are
quite analogous, and are consistent with intercalation.
The geometry ofthe complex is also likely to be similar
to daunomycin (85,101). Similar to the apparent lack of
a base composition preference for daunomycin, there is
little evidence for a base composition preference for
these anthracyclines. Nogalamycin poses a particular
problem as it also intercalates, in spite ofthe two gly-
cosidic rings (one at each end) that are too sterically
demanding to permit intercalation during normal DNA
breaking. Itexhibits astrictATpreference, and Collier
et al. (102) reasonably surmise that local melting ofthe
DNA is required for the intercalation process. Simu-
lationofthe structure oftheintercalatedcomplexplaces
the nogalose ring snugly within the minor groove
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(22,102), and provides a structural explanation for the
pronounced decreaseinDNA affinity observedforthose
nogalamycin analogs lacking it as a substituent. The
curious feature within the nogalamycin family is that
optimnization ofantitumor activity coincides with a sub-
stantial decrease in DNA affinity; menogarol lacks the
C-10 carbomethoxy and the C-7 nogalose (but does con-
tain a 7R-methoxyl) (23,24). Thus neither DNA affinity
nor RNA synthesis inhibition correlate well withtumor
cytotoxicity within the nogalamycin family; and data
from the other families as well suggest this to be an
evenmore general statement. The present understand-
ing of the anthracycline structure-activity relationship
does not demand intercalation as a necessary part of
the tumor cytotoxicity.
A development that has justifiably attracted consid-
erable attention-as its implications extend beyondthe
anthracyclines-is the effect of DNA intercalation on
the mammalian topoisomerase II enzyme. In addition,
this development may address the difficulty discussed
in the preceding paragraph. Following the seminal ob-
servations ofKohn, Ross and colleagues (103,104) using
thealkaline elutiontechniquetomonitor DNAintegrity
(105), the presence of single and double strand DNA
breaks was found to be a consequence ofboth an inter-
calating agent (those that are effective include Adria-
mycin, 5-iminodaunorubicin, ellipticine and m-AMSA)
and covalently bound protein at the cleavage site. The
identity ofthis protein as the topoisomerase II is con-
firmed by several research groups (104,106-111). The
role of this enzyme, summarized from these publica-
tions, inproducingthe DNAstrandbreaksisasfollows.
Topoisomerase II catalyzes the crossing oftwo double-
stranded DNAsegments viathe generation oftransient
double-stranded DNA breaks involving covalent bond
formation between a tyrosine of the enzyme and the
DNA strand. It is an enzyme activity that is presumed
to parallel transcriptional activity, and hence tumor
cells might remain more sensitive to the inhibition of
this enzyme's activity. Exposure to DNA, containing
certain intercalated molecules, results in the formation
of a stable enzyme-DNA complex, trapped at the cov-
alent intermediate state. Denaturation then unmasks
this complex-retaining the now-unfolded enzyme at
the strand end-providing a lesion that appears upon
in vitro analysis as either a single or double strand
break. Likewise, removal of the intercalator without
denaturation restores enzyme activity as evidenced by
the resealing of the strand. On the surface, the above
biochemistry is appealing in that it presents at the mo-
lecular level and in a unique fashion the antitumor an-
tibiotic as a molecule specifically targeted to the DNA.
On even slightly greater scrutiny however the com-
plexity that must rest within this apparently straight-
forwardprocess emerges, astherationale forthisevent
is as yet absent. Certainly not all intercalators are an-
titumorantibiotics, anditisnecessarytocorrelatethose
that are with theirrelative efficacy in order to properly
relatethisphenomenon asamoleculareventtotheover-
all biological properties observed. There can now be no
doubt that the actual details of the stabilization of the
topoisomerase-intercalator DNA complex are very
muchinfluencedbytheintercalatorstructure(106-111).
This is most clearly evidenced by comparison of the
ortho and meta AMSA isomers, which possess equiva-
lent intercalative ability yet only the meta isomer pos-
sesses potent cytotoxic activity and topoisomerase in-
hibition (110). They differ also in sequence specificity
(110), and in their single- to double-strand break ratios
(107). Two possibilities exist for the topoisomerase-
DNA complex stabilization by the intercalator. In the
first, the confornational deformation in the DNA in
response to intercalation is expressed in the complex
stabilization; oralternatively amore subtlerelationship
exists between the antibiotic and the topoisomerase,
perhaps with the antibiotic as an allosteric effector of
sorts. Although a decision is premature, the continuing
observations favor the latter choice, as argued by Liu
and colleagues (111). Nonetheless the excellent corre-
lation between cytotoxicity and topoisomerase stabili-
zation within the AMSA and ellipticine families secures
this phenomenon as a central focus for antitumor re-
search. Lastly the notion of an allosteric role for the
anthracyclines (as distinct from a pure intercalative
role) is attractive from the point ofview that there are
several antitumor anthracyclines with weak in vitro
DNA affinity that yet retain antitumor ability, such as
the N-alkylanthracyclines (94) and menogarol (24). An
unrelated yet complementary observation by Israel,
Chuang, and colleagues (94,95) is that the N-alkylad-
riamycins retain a potent ability to inhibit eukaryotic
RNA polymerases; again, this phenomenon cannot in-
volve intercalation. It may follow that elements ofthe
anthracycline structure as seen by the topoisomerase
and other enzymes-rather than by the DNA as ex-
pressed byintercalation-define the cytotoxic relation-
ship with DNA.
Implicit in the above discussion is that the topoiso-
merase inhibition is a nonredox-controlled event. This
is directly confirmed experimentally, by the lack of a
requirement for a reducing agent in the duplication of
this event in vitro, and by the relative efficacy of 5-
iminodaunorubicin. This analog is poorly reduced, yet
retains an excellent ability to stabilize the topoisomer-
ase-DNAcleavablecomplex. Whetherintercalation and
topoisomeraseinhibition arethemselves sufficientto ac-
count forall anthracycline-mediated DNAdamage isby
no means certain. In particular, there remains the pos-
siblity that the redox properties enumerated in the
above sections permit DNAdamage. This may occurby
either of two circumstances; first where aerobic redox
cyclingleads tooxygen-radical mediated DNA damage,
and the second where anaerobic activation to a quinone
methide, proximal to a susceptible functional group of
the DNA, enables covalent modification to occur. Un-
fortunately, evidence of only the most circumstantial
sort may be brought forth in support ofeither hypoth-
esis. The proper relationship ofthe two possible redox
phenomena is therefore uncertain. A summary oftheir
present status is provided.
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Anthracycline-Mediated Damage to
Oligonucleotides
Based upon Lown and colleagues' observation (112)
that aerobic anthracycline reduction resulted in DNA
cleavage and their own extensive studies of anthracy-
cline metabolism, Bachurand colleagues proposed (113)
that the cytotoxic expression ofthe anthracyclines de-
rived from the site specific generation of free radicals
targeted to the DNA. Under aerobic conditions, these
radicals could generate HO from the H202 produced
concurrently, while anaerobically covalent labeling by
the semiquinone-derived quinone methide was possible.
The essentials ofpart ofthis proposal are supported by
several experimental studies confirming the aerobic
sensitivity of DNA to reductively activated anthracy-
clines. BerlinandHaseltine (90)observedthatanexcess
ofAdriamycin relative to DNA, upon enzymatic reduc-
tive activation, gave DNA strand scission during turn-
over(butnotafterward)underaerobicconditions(much
less scission is observed anaerobically). No sequence
specificity is apparent. Examining a series of anthra-
cycine analogs, Lown et al. (114) found an excellent
correlation between the rate of microsomal reduction
and the extent of aerobic degradation. Gutteridge and
Toeg (60) observe that the efficiency of this reaction
increased under "partially" anaerobic conditions, and
provide evidence for an absolute metal ion requirement
(as was also surmised by Lown et al.). The mechanistic
events of this process are not known, but quite likely
involve the hydroxyl radical (or its metal-bound equiv-
alent) as a hydrogen atom abstractor. A possible initi-
ation stepishydrogen atomlossfromthe2' or3' carbon
ofthe deoxyribose, followed by fragmentation. Should
this prove to be the case, the DNA cleavage would be
analogous to what is believed to occur for bleomycin
(115). Other perspectives in metal ion modulation of
anthracyclineredoxprocessesare discussed previously.
A related issue is the competence ofthe intercalated
anthracyclineasanoxidant. Thereisgeneralagreement
that intercalation severely diminishes the yield of the
semiquinone from anaerobic enzymatic reduction
(32,90). However, the inference that anthracycines
cease to behave as oxidants upon intercalation is pre-
mature. In particular, the rationalization that since the
DNA now limits access or approach to the anthracy-
clines, they become incapable of electron transfer, is
unwarranted. The prosthetic groups ofcytochrome c or
flavodoxin-just two examples-are well protected by
the protein polypeptide, with little loss in their redox
capacity. There is no reason to suppose that the an-
thracyclines will retain or lose redox activity before the
experimental data are available. The less intense EPR
signal for the semiquinone observed thus far might be
a consequence of the anthracycline being unavailable
due to steric reasons; or as wellto an effect ofthe DNA
on the two one electron potentials to favor even more
overall two electron reduction. Further, the number of
enzymatic and chemical reducing agents thus far ex-
amined is small. It is conceivable that certain enzymes
are more capable than others, given a situation where
perhaps the anthracycline intercalated to the mitochon-
drial DNA is more available for redox processes than
the DNA in the nucleus. Youngman and Elstner (116)
have presented evidence for 02- as a competent inter-
calated anthracycline reducing agent. In brief, there is
simply too little experimental data concerned with the
kinetic and chemical consequences ofintercalation with
respect to the anthracycline redox processes, to make
any substantial conclusion for either aerobic or anaer-
obic events.
The onlypresent evidence forcovalent labelingofthe
DNAby anthracyclines is circumstantial, derivingfrom
Sinha's studies (117,118) conducted under anaerobic
conditionsusingbothchemicalandenzymaticreduction.
Following anthracycline activation, the DNA is exten-
sively purified by high salt extraction and ethanol pre-
cipitation, conditions which should remove all drugthat
is merely intercalated. Underthese conditions, some of
the anthracycline is retained, presumably covalently
bound somewhere within the DNA. Significantly lower
yieldsareobtainedusingthe(7-hydroxy)aglycones, that
are unable to intercalate. Similar experiments are re-
ported for protein (119), that also purport to establish
covalent labeling. Possible candidates for the reactive
intermediate are the semiquinone; the seimquinone-de-
rived quinone methide; or the hydroquinone-derived
methide. As is discussed previously, only the latter is
an attractive candidate in terms ofestablished chemical
competence, and its bimolecular reactivity as either an
electrophile or nucleophile is low. Whether the associ-
ation to DNA improves the situation (covalent reaction
atC-7thusbecomesineffectanintramolecularreaction)
is an open question. In brief, in spite of the extensive
literature presuming akineticand chemical competence
for anthracyclines as reductively activated pro-drugs
targeted to the DNA, the available experimental evi-
dence is meagerand incomplete. There is nowhere near
the level ofstructural detail as ispresently available for
mitomycin c (120), a quinone antitumor antibiotic that
all evidence indicates operates as a bioreductive alky-
lator toward DNA.
This discussion on the chemical alterations to DNA
effected by the anthracyclines concludes with a most
interesting observation (121). Treatment of DNA con-
taining intercalated Adriamycin with the uvrABC en-
donuclease, a DNA repair enzyme specific for bulky
covalent lesions, results in no excision of DNA. How-
ever recovery of DNA from E. coli bacteria, deficient
inthisenzyme's activity, thathadbeenexposedtoAdri-
amycin did result in DNA excision. Furthermore the
mutant was found exquisitely sensitive to Adriamycin
as a toxic agent. These circumstances indicate that the
anthracyclines operate upon the DNA in vivo in a fash-
ion dissimilar to mere intercalation. Kacinski and Rupp
offer as a working hypothesis that a correlation may
exist between the antibacterial activity and the extent
ofDNA damage, and that this correlation may also ex-
tendtosomeaspectoftheanthracycline clinicalactivity.
Clearly, this hypothesis is attractive, and will perhaps
12ANTHRACYCLINE ANTITUMOR ANTIBIOTICS
become even more fetching when the molecular lesion
involved maybedescribed. Asitnowstands DNAdam-
age via aerobic degradation, covalent labeling by the
quinone methide, or even related to the topoisomerase
cleavable complex provide reasonable explanations.
The Cellular Membrane as an
Anthracycline Target
Membrane Association as a Cytotoxic
Event
As is the case forthe nucleic acids, the cellular mem-
brane is also a potential target of both nonredox and
redox anthracycline processes. This section considers
the present status of the former. The rationale for a
search beyond nucleic acids-and to the membrane
as the cytotoxic target for the anthracyclines is suc-
cinctly defended by Tritton and colleagues (122). Ar-
guing that the absence of a correlation between the
cytotoxic activity ofthe anthracyclines and either DNA
affinity or damage demands that other possibilities be
considered, they identify three criteria by which the
cellmembrane maybe established asadrugtarget. The
first criterion is that the drug interact with the mem-
brane; the second that it alter the membrane's prop-
erties; and the third that this alteration be necessary
and sufficient for cell cytotoxicity. There is a multitude
ofevidence attestingtothe ability ofthe anthracyclines
with respect to the first two criteria (123). A strong
association of anthracyclines to membranes having lip-
ids with acidic head groups is well proven (124). Fur-
ther, anarrayofmemrbranepropertiesarefoundaltered
by the presence ofanthracyclines. These include phos-
pholipid structure, glycoprotein synthesis, the trans-
portofsmallmolecules andions, andmembranefluidity.
Withrespecttomembranefluidity, anattempthasbeen
made to correlate it with the relative amount ofoxygen
present, and with the development of drug resistance
(125). Under hypoxic conditions, there was an increase
influiditythatdidnotcorrelatewithdifferencesinmem-
brane perneability to the anthracyclines. It did, how-
ever, seemtorelate toanasyetunidentifiedmechanism
of anthracycline resistance. In general, resistant cells
display a lowered capacity for anthracycline accumu-
lation which is attributed to an enhanced drug efflux
system. (Resistance also does not involve an increased
capacity for anthracycline metabolism nor an increased
sensitivity toward oxygen radicals) (126). Yee et al.
(127) have attempted to locate an anthracycine mem-
brane receptor by photolytic labeling. Labeling was
equally successful under conditions where the drugwas
able and was not able to enter the cell, indicating a
strong membrane interaction. The photolytic coupling
is to a protein, as the bound drug is freed upon treat-
ment with a protease. However the yield ofphotolytic
labelingwasneitherspecificnorsaturable, didnotoccur
at the drug transport locus, and did not affect the cell
viability. Since the yield did increase in direct propor-
tion to the cell's level of drug resistance, the protein
that is labeled may be associated with the resistance
process, with the membrane property most likely af-
fected beingfluidity. Thus association ofanthracyclines
and the alteration of membrane properties is proven.
The fulfillment ofthe third criterion is quite a bit more
problematical.
Theexperimentalapproachthathasbeenusedtosep-
aratethecellmembraneactivitiesfromtheintracellular
processes is the use of anthracyclines covalently im-
mobilized to polymeric microspheres (128,129). Pro-
vided that the drug is truly immobilized, this prevents
the anthracycline from beinginternalized by the cell. It
appears that loss ofthedrugfromthemicrosphere does
not occur, and that the ensuing cytotoxic events that
are observed correspond to a membrane-associated cy-
totoxic event. At equivalent concentrations, the poly-
mer-bound anthracycines are equally cytotoxic as the
free drug. Following exposure of the cell to polymer-
bound anthracycline, cell-surface microvilli are lost and
replaced with blebs; holes appearinthe membrane con-
comitant with cell death (130). A reasonable question,
however, is the relevance of this cytotoxic process to
that produced by the free drug, which will not neces-
sarily remain immobile at the cell membrane. The an-
swer here is unavailable. As an illustration ofthe com-
plexity and peculiarity of this overall process, a most
interesting experiment by Rogers and Tokes (131) is
offered in point. It is found that an anthracycline dias-
tereomer (7R,9R-4-demethoxydaunorubicin) that is to-
tally inactive as the free drug, displays potent cytotox-
icity when immobilized to the polymer support. While
this underscores the role of the membrane in any hy-
pothesis for anthracycline cytotoxicity, the experiment
is difficult torationalize because ofthe very appreciable
sensitivity (with respect to anthracycline structure) of
cell cytotoxicity in vivo. In closing, attention is called
to some recent developments concerning a possible ef-
fect of drugs in general (132), and anthracyclines in
particular (133-135), on the Ca"2 balance. This process
may influence both cell toxicity and cell resistance to
the anthracyclines.
From another perspective the cell membrane is not
a target but an obstacle. Ifthe cytotoxic target of the
anthracycline rests within the cell, then the membrane
must be circumvented for the drug to attain access. As
different cells have different receptors, a drug delivery
system that takes advantage ofa unique difference be-
tweentheneoplastic andnornalcellwouldachieveboth
specificity and increased potency. Unfortunately as yet
this difference must be sought empirically. Among the
carriers so farinvestigated arelow-densitylipoproteins
(136,137), lysosomal proteins (138), antibodies and im-
munoglobin (139,140), and anionic liposomes (141).
While some ofthesecomplexesdoimproveactivity, this
maybe aconsequence ofanynumberofpossibilities and
not necessarily to more selective targeting.
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Cardiotoxicity as a Consequence of
Anthracycline-Induced Lipid Peroxidation
The ability of the anthracyclines to divert electrons
fromlowpotentialflavin- andmetal-containing enzymes
to oxygen, yielding 02- and H202, and ultimately the
hydroxyl radical, suggests lipid peroxidation as a po-
tentially deleterious physiologicalresult (6,142). Recent
evidence points to a particular contribution ofthis pro-
cess to the cumulative cardiomyopathy, rather than to
the antitumor activity (6,47,72,142,143). The enhance-
ment of lipid peroxide concentration following anthra-
cycline administration is readily demonstrated, as dis-
cussed by Thayer (144), who observes a dose and time
dependent rise in serum neutral lipid peroxides with
Adriamycin in rats. There are further data indicating
an identical effect to the heart (145,146), under dosages
which are sufficient to develop the cardiomyopathy.
Thatthis phenomenon appears inthe heart, ratherthan
in the liver-which is more active in anthracycline re-
ductive metabolism-is believed to reflect the heart as
a tissue particularly susceptible to this reaction and its
consequences. The heart has a high rate ofrespiration
andiswelloxygenated. Thisprovides opportunity. Fur-
thermore, the relative ability of the heart to defend
itself against oxygen reduction may be poorer than
other tissues. It contains much lower levels ofcatalase
and superoxide dismutase than found inthe liver (6,71),
and while the levels of the third enzyme, glutathione
peroxidase, isidenticaltothatintheliver, anthracycine
administration depresses its activity. This may occur
by an inadequate mobilization of selenium for this en-
zyme (147). The overall situation may be exacerbated
by additional circumstances. The steady state levels of
both NADPH andglutathione mayfall as a consequence
ofthe futile oxygen reduction, leading to a further de-
terioration in reduced oxygen detoxification. The abun-
dance ofmetal and hemeproteins and enzymes mayalso
aggravate this situation by either direct metal chelation
to the anthracycline or iron-heme catalyzed oxygen ac-
tivation. A situation is envisioned where the heart's
intrinsic ability to detoxify the reduced oxygen species
is overwhelmed, atwhichtime lipid peroxidation occurs
on a scale sufficient to adversely effect the heart's per-
formance. Together, theseobservationsandconjectures
are reasonably consistent with the delayed yet cumu-
lative dose-dependent nature of the heart damage by
the anthracyclines.
The direct involvement of lipid peroxidation in the
cardiac damage is substantiated by other experimental
approaches. Anthracyclines with adiminished redox ca-
pacity (such as 5-iminodaunorubicin) or an inability to
chelate metals (such as 11-deoxyanthracycines) appear
in vitro as less cardiotoxic agents. Interestingly, this
frequently coincides with a loss in antitumor potency.
In contrast anthracyclines with an enhanced redox ca-
pacity (such as carminomycin or 4-demethoxydauno-
rubicin) are capable ofenhanced lipid peroxidation and
cardiotoxicity (148,149). A potential benefit of antioxi-
dants may be to augment the heart's capacity in con-
trolling free radical damage. This is well established in
in vitro and animal studies (6,150), although no suc-
cessful clinical strategy for minimizing the cardiotox-
icity has yet to evolve. Additional studies concerned
with the effect ofa deliberate abolition ofanthracycline
redox activity (discussed below in the concluding sec-
tion) are also consistent with the cardiotoxicity as an
oxygen-dependent redox process. Yet, at present, the
finalproofremainsabsent. Evenratherstraightforward
in vitro experiments offer puzzles not reconcilable with
simple chemistry (148). As an example ofthe degree of
complexity posed by this phenomenon, the develop-
ments with mitoxantrone are offered. This nonanthra-
cycline anthraquinone antitumor antibiotic is clearly re-
dox-impaired relative to Adriamycin (151), and, indeed,
early studiesindicated adecreased cardiotoxicity. More
recentlyhoweverthe situationhasblurred, andthepos-
sibility is presented that this antitumor antibiotic is as
cardiotoxic as the anthracyclines (152,153). Once again,
the difficulty in connecting chemical observation to
physiological consequence is emphasized. We may con-
clude however that the sum of the available evidence
supports lipidperoxidationasthecardiotoxicevent, and
that it is the proper relationship of lipid peroxidation
as a cause and the cardiotoxicity as an effect that now
merits closer attention.
Envol
Relation of Redox Activity to the
Antitumor Activity
The urgency behind the study ofanthracycline chem-
istry derives, of course, from their antitumor efficacy.
Their capacity as redox agents may, in the proper cir-
cumstances, be exertedagainstbothcell membraneand
nucleic acids, and, as likely, selected enzymes as well.
Given their extraordinary potency, it is probable that
only one ofthese targets in vivo suffices to destroy the
neoplastic cell in a precise and methodical fashion. It is
therefore with adiscordant note ofresignation that this
review must contain the statement that neither the cy-
totoxic event, northe relationship ofthe redox activity,
has been properly placed into the context of the an-
thracyclines as antitumor antibiotics.
Yet new experimental approaches are emerging to
attack this conundrum, drawn from the reservoir of
basic chemical and biochemical knowledge now accu-
mulated from the studies summarized in the review. In
particular, there ispreliminaryprogressindicatingthat
catalytic redox turnover contributes a significantly
greater extent to the host cytotoxicity, rather than to
the antitumor activity. Several different yet concep-
tuallyrelatedstudiesbearonthispoint. Anexamination
ofanthracycline-sensitive tumorcells suggeststhatnei-
therthe presence nor absence ofoxygenis acomponent
ofthe tumor sensitivity to the anthracycline (154,155).
The presumption to be drawn is that the tumor cyto-
toxicity does not involve any redox event. On the pre-
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sumptionthatxanthineoxidasecontributes significantly
to anthracycline metabolism and so serves to diminish
the anthracycline titer with respect to the antitumor
locus, Schwartz(68,156)hasexaminedtheconsequences
ofthe co-administration ofa xanthine oxidase inhibitor
upon survival times ofanimals having L1210 leukemia.
Significant increases in the survival time are observed.
The simplest interpretations ofthis effect are that an-
thracycline reductive activation is at best a chemically
innocuous event that causes a decrease in the anthra-
cycline potency at the antitumor locus; and at worst is
achemically damaging event that maybe forestalled as
the anthracycline is diverted to its proper place. Like-
wise, Banks et al. (157), recognizing the specific and
efficient reduction of anthracyclines by the trimethyl-
morpholinyl radical, observe that the prompt adminis-
tration of the precursor to this radical, subsequent to
an otherwise lethal dose of Adriamycin, rescues the
animal from death. This may be done without interfer-
ence with the antitumor activity (T. Koch, unpublished
data). This simple experiment holds the promise that
strategies based upon minimizing catalytic redox activ-
ity due to the anthracycline's presence may favorably
alter the therapeutic ratio. This same conclusion may
be drawn from a study by Hrushesky, Eaton, and col-
leagues (158). Onthe premise that atransientreduction
in NADPH levels might forestall toxic catalytic redox
cycling while preserving the anthracycline for the an-
titumorlocus, co-administration ofmethylene blue with
Adriamycin in L1210 inoculated mice was examined. A
significant reduction in the Adriamycin lethality is
found, without any effect on the antineoplastic activity.
Together, thesethree studies suggestthatthehosttox-
icity and the antitumor activity are dissociable pro-
cesses, andofferanexperimentalbasisforfurthereffort
to vindicate this claim.
Whether the antitumor locus is found at the nucleic
acids, the membranes, or in a specific redox-controlled
event remains unknown. What is clearisthatthe study
of the basic chemical and biochemical principles by
whichtheanthracyclines arelimited, hasbeenrewarded
with the development of experimental hypotheses
which allow a rational manipulation of the drugs' bio-
logicalactivity. Itisinthis simplefactthatallwhohave
labored in the anthracycline field may take comfort.
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